Decision about extra shareholders meeting and application for delisting

Uppsala August 21, 2006. GE Healthcare, which after the completion of the public offer to the shareholders in Biacore, owns more than 98% of the shares in Biacore, has requested the board of directors of Biacore to convene an extraordinary shareholder’s meeting in Biacore as soon as possible for the election of a new board of directors for the company.

As a result hereof, the board of directors of Biacore has resolved to convene an extraordinary shareholders’ meeting. The date for such shareholders’ meeting will be provided in the notice for the shareholder’s meeting. Further, the board of directors has resolved to apply for delisting of Biacore from the Stockholm Stock Exchange’s O-list since Biacore no longer fulfils the Stockholm Stock Exchange’s requirements regarding the number of shares which must be publicly owned. Biacore International AB (publ) Board of Directors – Ends – Fort further information please contact: Erik Walldén, President and CEO, +46 70 225 22 70 About Biacore Biacore is a global supplier of systems for protein interaction analysis, an area of increasing importance for scientists in the academic, pharmaceutical, biotechnology and diagnostic markets. The Company's systems generate unique data on the interactions between proteins and other molecules, including small molecules such as drug candidates. During research, development and manufacture, these data give insights into protein functionality, elucidate disease mechanisms and play a key role in the critical decisions needed for efficient development and production of therapeutics. Biacore’s products are used in key areas such as antibody characterization, proteomics, lead characterization, immunogenicity, biotherapeutic development and production. The Company offers a range of products to meet specific application needs. Customers include leading life science research centers, all of the leading global pharmaceutical companies, and a large number of companies in the emerging biotechnology sector. Biacore also markets food analysis solutions, providing key manufacturers with a system and ready-to-use kits for the determination of food quality and safety. The company has its own direct sales capability in the world's key markets (United States, Europe, Japan, China, Australia) and a distribution network in Asia-Pacific. Biacore was founded in 1984 and is listed on the Stockholm Stock Exchange (SSE:BCOR). Further information on Biacore can be found at: www.biacore.com